Gold prices steady above $3,400/oz on rate cut bets; PCE data awaited
Following this sale, LeSueur holds 91,253 shares in the company. The sale was conducted as part of a pre-established trading plan under Rule 10b5-1, which allows company insiders to set up a predetermined plan for selling stocks. While the company is not currently profitable, InvestingPro analysis indicates expected profitability this year, with 6 analysts revising earnings estimates upward. For deeper insights into Health Catalyst (NASDAQ:HCAT)'s valuation and growth prospects, investors can access the comprehensive Pro Research Report, available exclusively on InvestingPro. While the company is not currently profitable, InvestingPro analysis indicates expected profitability this year, with 6 analysts revising earnings estimates upward. For deeper insights into Health Catalyst's valuation and growth prospects, investors can access the comprehensive Pro Research Report, available exclusively on InvestingPro.
Following this sale, LeSueur holds 91,253 shares in the company. The sale was conducted as part of a pre-established trading plan under Rule 10b5-1, which allows company insiders to set up a predetermined plan for selling stocks.
In other recent news, Health Catalyst Inc. has been the subject of several significant upgrades by financial firms. KeyBanc Capital Markets upgraded the stock from Sector Weight to Overweight, setting a new price target of $9.00. This followed their analysis of credit card data indicating sustained healthy utilization levels, which is anticipated to positively influence hospital technology budgets. They also cited the early stages of margin expansion leading to healthier technology revenue growth.
Piper Sandler showed continued optimism for Health Catalyst, increasing the price target on the company's stock to $12.00, up from the previous $11.00. Their adjustment incorporated the revised calendar year 2024 guidance provided by Health Catalyst, which anticipates a robust year-over-year growth of approximately 50% in adjusted EBITDA for calendar year 2025.
Stephens, a financial services firm, also increased the price target for Health Catalyst to $9.00, up from the previous $7.00, following the company's positive third-quarter performance. In addition to these analyst upgrades, Health Catalyst disclosed its third-quarter financial results for 2024, indicating a positive profit and loss execution and a revenue mix shifting back towards software. The company's leadership team expressed a positive outlook for Health Catalyst's growth trajectory and provided financial projections for the remainder of 2024 and the full year of 2025. These are the recent developments for Health Catalyst.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.